Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors

Lu Zhou, Ying Liu, Weilin Zhang, Ping Wei, Changkang Huang, Jianfeng Pei, Yaxia Yuan, Luhua Lai

Research output: Contribution to journalArticlepeer-review

123 Scopus citations


A series of isatin derivatives were synthesized and tested against SARS CoV 3C-like protease. Substitutions at the N-1 and C-5 positions were examined to elucidate the differences in substrate binding sites of the rhinovirus 3C protease and SARS CoV 3C-like protease. Compound Sf shows significant inhibition with an IC50 of 0.37 μM. Further study showed that, unlike the irreversible covalent binding of isatin derivatives to human rhinovirus 3C protease, the compounds tested in this study are all noncovalent reversible inhibitors.

Original languageEnglish (US)
Pages (from-to)3440-3443
Number of pages4
JournalJournal of Medicinal Chemistry
Issue number12
StatePublished - Jun 15 2006
Externally publishedYes

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine


Dive into the research topics of 'Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors'. Together they form a unique fingerprint.

Cite this